Company · CIK 0001479290
Revance Therapeutics, Inc.
Exchange
—
Entity type
operating
Fiscal year end
Dec 31
Headquarters
DE
Search this company’s filings
Search features10 guest searches · Free accounts get 10 a day · No credit card
On the record
Recent filings
- 8-KCurrent report0001193125-25-021403 · 345.7 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-25-001461 · 255.8 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-049072 · 202.2 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-048749 · 1.5 MBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-048480 · 196.4 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-048244 · 198.3 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-048023 · 198.7 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-047831 · 194.2 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-047293 · 193.9 KBSEC(opens sec.gov)
- 8-KCurrent report0001140361-24-045956 · 192.9 KBSEC(opens sec.gov)
Insiders
- Allouche CyrilPrincipal Accounting Officer
- Beraud JillDirector
- Bertolino Arthur PeterEVP and Chief Medical Officer
- Browne L DanielDirector, CEO and President
- BYRNES ROBERT FDirector
- Coric VladDirector
- Eastman Ronald WDirector, 10% Owner
- Foley Mark JDirector, President & CEO
- Gangolli Julian SDirector
- GARDNER PHYLLISDirector
Tickers
No tickers on record.
Addresses
business
1222 DEMONBREUN STREET SUITE 2000
NASHVILLE, TN, 37203
mailing
1222 DEMONBREUN STREET SUITE 2000
NASHVILLE, TN, 37203
Same industry